Cdt Equity Inc. (CDTTW) — SEC Filings

Cdt Equity Inc. (CDTTW) — 50 SEC filings. Latest: 8-K (Dec 12, 2025). Includes 29 8-K, 5 SC 13G/A, 4 10-Q.

View Cdt Equity Inc. on SEC EDGAR

Overview

Cdt Equity Inc. (CDTTW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 12, 2025: CDT Equity Inc. filed an 8-K on December 12, 2025, reporting on events that occurred on December 8, 2025. The filing indicates an entry into a material definitive agreement, unregistered sales of equity securities, and includes financial statements and exhibits. The company, formerly known as Condui

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 6 bearish, 43 neutral, 1 mixed. The dominant filing sentiment for Cdt Equity Inc. is neutral.

Filing Type Overview

Cdt Equity Inc. (CDTTW) has filed 29 8-K, 4 10-Q, 1 10-Q/A, 3 DEF 14A, 2 8-K/A, 2 10-K, 5 SC 13G/A, 1 SC 13G, 1 SC 13D/A, 1 S-1/A, 1 S-1 with the SEC between Feb 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent SEC Filings (50)

Cdt Equity Inc. SEC Filing History
DateFormDescriptionRisk
Dec 12, 20258-KCDT Equity Inc. Files 8-K on Material Agreement & Equity Salesmedium
Nov 13, 202510-QCDT Equity's Losses Widen Amid Strategic Shift, Cash Infusion from ATMhigh
Oct 9, 20258-KCDT Equity Inc. Files 8-K on Security Holder Rightsmedium
Aug 14, 202510-Q/ACDT Equity Inc. Files Q1 2025 10-Q Amendmentlow
Aug 8, 20258-KCDT Equity Inc. Files 8-K: Director Changes, Bylaw Amendmentsmedium
Jul 8, 2025DEF 14AConduit Pharma Seeks Share Reserve Boost, Board Election at August AGMmedium
Jun 9, 20258-KConduit Pharmaceuticals Files 8-K: Material Agreement & Equity Salesmedium
Jun 3, 20258-KConduit Pharmaceuticals Files 8-K on Shareholder Nominationsmedium
May 16, 20258-KConduit Pharmaceuticals Files 8-K on Security Holder Rightsmedium
May 15, 202510-QConduit Pharmaceuticals Files Q1 2025 Reportlow
May 6, 20258-KConduit Pharmaceuticals Files 8-K on Shareholder Voteslow
Apr 25, 20258-KConduit Pharmaceuticals Files 8-K: Accountant Change & Financialsmedium
Apr 16, 20258-KConduit Pharmaceuticals Announces Board and Compensation Changesmedium
Apr 4, 20258-KConduit Pharmaceuticals Reports Material Agreement and Equity Salesmedium
Apr 2, 20258-K/AConduit Pharmaceuticals Files 8-K/A Amendmentlow
Apr 1, 20258-KConduit Pharmaceuticals Files 8-Kmedium
Mar 28, 202510-KConduit Pharmaceuticals Files 2024 10-Kmedium
Mar 6, 20258-KConduit Pharmaceuticals Files Current Reportlow
Feb 19, 20258-KConduit Pharmaceuticals Faces Delisting, Terminates Agreementhigh
Feb 11, 20258-KConduit Pharmaceuticals to Acquire 03 Life Sciencesmedium

Risk Profile

Risk Assessment: Of CDTTW's 44 recent filings, 6 were flagged as high-risk, 25 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Cdt Equity Inc. Financial Summary (10-Q, Nov 13, 2025)
MetricValue
RevenueN/A
Net Income-$7.1M
EPSN/A
Debt-to-EquityN/A
Cash Position$3.8M
Operating MarginN/A
Total AssetsN/A
Total DebtN/A

Key Executives

  • David Tapolczay

Industry Context

CDT Equity Inc. operates in a dynamic sector where innovation and capital are crucial for growth. Companies in this space often face intense competition and require significant investment in research and development. The ability to secure ongoing funding is paramount, especially for early-stage or growth-focused entities.

Top Tags

corporate-governance (9) · material-agreement (8) · equity-sale (6) · filing (5) · pharmaceuticals (5) · amendment (4) · 10-Q (4) · governance (4) · financial-obligation (4) · financials (3)

Key Numbers

Cdt Equity Inc. Key Metrics
MetricValueContext
Net Loss (Q3 2025)$7.1MIncreased from $6.5M in Q3 2024
Net Loss (9M 2025)$17.9MIncreased from $15.4M in 9M 2024
Accumulated Deficit$47.0MAs of September 30, 2025, indicating significant historical losses
Cash and Cash Equivalents$3.8MAs of September 30, 2025, up from $0.6M at Dec 31, 2024
Cash Used in Operating Activities (9M 2025)$10.9MIncreased from $5.9M in 9M 2024, showing higher burn rate
Proceeds from ATM Program$17.9MKey source of financing for the nine months ended September 30, 2025
Common Shares Outstanding1,276,574As of September 30, 2025, significantly up from 11,540 at Dec 31, 2024, indicating dilution
General & Administrative Expenses (9M 2025)$11.3MIncreased from $8.7M in 9M 2024
Research & Development Expenses (9M 2025)$4.3MIncreased from $3.2M in 9M 2024
Period End Date2025-03-31The financial information pertains to this date.
Quarter Start Date2025-01-01The financial information pertains to this period.
Previous Year End Date2024-12-31Comparative financial data may be presented.
Central Index Key0001896212Unique identifier for CDT Equity Inc.
Filing Date20250808Date the 8-K was submitted to the SEC
Number of directors to be elected5Each for a one-year term expiring at the next annual meeting

Forward-Looking Statements

  • {"claim":"Polar Asset Management Partners Inc. will maintain a significant, albeit passive, stake in Conduit Pharmaceuticals Inc. for the foreseeable future.","entity":"Polar Asset Management Partners Inc.","targetDate":"12/31/2024","confidence":"medium"}

Related Companies

CDT

Frequently Asked Questions

What are the latest SEC filings for Cdt Equity Inc. (CDTTW)?

Cdt Equity Inc. has 50 recent SEC filings from Feb 2024 to Dec 2025, including 29 8-K, 5 SC 13G/A, 4 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of CDTTW filings?

Across 50 filings, the sentiment breakdown is: 6 bearish, 43 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Cdt Equity Inc. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Cdt Equity Inc. (CDTTW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Cdt Equity Inc.?

Key financial highlights from Cdt Equity Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for CDTTW?

The investment thesis for CDTTW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Cdt Equity Inc.?

Key executives identified across Cdt Equity Inc.'s filings include David Tapolczay.

What are the main risk factors for Cdt Equity Inc. stock?

Of CDTTW's 44 assessed filings, 6 were flagged high-risk, 25 medium-risk, and 13 low-risk.

What are recent predictions and forward guidance from Cdt Equity Inc.?

Recent forward-looking statements from Cdt Equity Inc. include guidance on {"claim":"Polar Asset Management Partners Inc. will maintain a significant, albeit passive, stake in Conduit Pharmaceuti.

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.